Suppr超能文献

局灶性脑缺血和抗磷脂抗体患者复发性血栓栓塞事件的风险。中风研究组中的抗磷脂抗体。

Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group.

作者信息

Levine S R, Brey R L, Joseph C L, Havstad S

机构信息

Department of Neurology, Henry Ford Hospital, Detroit, Mich.

出版信息

Stroke. 1992 Feb;23(2 Suppl):I29-32.

PMID:1561671
Abstract

Antiphospholipid antibodies are a marker for an increased risk of thrombosis, including stroke and transient ischemic attacks. Prior studies suggest that patients with these antibodies and thrombosis may be at increased risk for recurrent thrombotic events. We prospectively evaluated 75 patients with antiphospholipid antibodies and cerebral or ocular ischemia for recurrence of thrombosis. Twenty-six patients (35%) experienced a recurrent stroke or transient ischemic attack, with a mean time to recurrence of 1.18 years. Hypertension significantly increased the risk of a recurrent transient ischemic attack. Patients with coronary artery disease were three times as likely as those without to have a recurrent stroke or transient ischemic attack. There was a trend for treatment with a combination of aspirin and dipyridamole to reduce the risk of recurrent thrombotic events after adjusting for sex and ethnicity.

摘要

抗磷脂抗体是血栓形成风险增加的一个标志物,包括中风和短暂性脑缺血发作。既往研究表明,有这些抗体且发生血栓形成的患者复发性血栓事件的风险可能增加。我们前瞻性地评估了75例患有抗磷脂抗体且有脑或眼部缺血的患者的血栓形成复发情况。26例患者(35%)经历了复发性中风或短暂性脑缺血发作,复发的平均时间为1.18年。高血压显著增加了复发性短暂性脑缺血发作的风险。患有冠状动脉疾病的患者发生复发性中风或短暂性脑缺血发作的可能性是未患冠状动脉疾病患者的三倍。在对性别和种族进行校正后,阿司匹林和双嘧达莫联合治疗有降低复发性血栓事件风险的趋势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验